vorinostat has been researched along with Leukemia, Myelomonocytic, Chronic in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Leukemia, Myelomonocytic, Chronic: A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sekeres, MA | 1 |
| Othus, M | 1 |
| List, AF | 1 |
| Odenike, O | 1 |
| Stone, RM | 1 |
| Gore, SD | 1 |
| Litzow, MR | 1 |
| Buckstein, R | 1 |
| Fang, M | 1 |
| Roulston, D | 1 |
| Bloomfield, CD | 1 |
| Moseley, A | 1 |
| Nazha, A | 1 |
| Zhang, Y | 1 |
| Velasco, MR | 1 |
| Gaur, R | 1 |
| Atallah, E | 1 |
| Attar, EC | 1 |
| Cook, EK | 1 |
| Cull, AH | 1 |
| Rauh, MJ | 1 |
| Appelbaum, FR | 1 |
| Erba, HP | 1 |
| Craddock, C | 1 |
| Galimberti, S | 1 |
| Canestraro, M | 1 |
| Khan, R | 1 |
| Buda, G | 1 |
| Orciuolo, E | 1 |
| Guerrini, F | 1 |
| Fazzi, R | 1 |
| Maffei, R | 1 |
| Marasca, R | 1 |
| Petrini, M | 1 |
1 trial available for vorinostat and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
2 other studies available for vorinostat and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Improving Outcomes in High-Risk Myelodysplasia: Festina Lente.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uni | 2017 |
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening | 2008 |